PMID- 35917563
OWN - NLM
STAT- MEDLINE
DCOM- 20220830
LR  - 20220830
IS  - 2167-9436 (Electronic)
IS  - 2167-9436 (Linking)
VI  - 41
IP  - 4
DP  - 2022 Aug
TI  - Development of an Anti-human CCR2 Monoclonal Antibody (C(2)Mab-9) by N-Terminal 
      Peptide Immunization.
PG  - 188-193
LID - 10.1089/mab.2022.0001 [doi]
AB  - The CC chemokine receptor type-2 (CCR2) is one of the members of the G 
      protein-coupled receptor superfamily, which are expressed on the cell surface of 
      immune and tumor cells. CCR2 binds to the C-C motif chemokine ligand 2 
      (CCL2)/monocyte chemoattractant protein-1 (MCP-1), which is produced by various 
      cells, including tumor and immune-related cells. Therefore, the development of 
      sensitive monoclonal antibodies (mAbs) for CCR2 has been desired for treatment 
      and diagnosis. In this study, we established a specific antihuman CCR2 (hCCR2) 
      mAb, C(2)Mab-9 (mouse IgG(1), kappa), using the synthetic peptide immunization 
      method. Flow cytometric and immunocytochemical results showed that C(2)Mab-9 
      reacted with hCCR2-expressing U937 (human histiocytic lymphoma) and natural 
      killer cells. Furthermore, C(2)Mab-9 showed the moderate binding affinity for 
      both cells. Conclusively, C(2)Mab-9 can be a useful tool for analyzing 
      hCCR2-related biological responses.
FAU - Tanaka, Tomohiro
AU  - Tanaka T
AD  - Department of Antibody Drug Development, Tohoku University Graduate School of 
      Medicine, Sendai, Japan.
FAU - Li, Guanjie
AU  - Li G
AD  - Department of Molecular Pharmacology, Tohoku University Graduate School of 
      Medicine, Sendai, Japan.
FAU - Saito, Masaki
AU  - Saito M
AD  - Department of Molecular Pharmacology, Tohoku University Graduate School of 
      Medicine, Sendai, Japan.
FAU - Suzuki, Hiroyuki
AU  - Suzuki H
AD  - Department of Molecular Pharmacology, Tohoku University Graduate School of 
      Medicine, Sendai, Japan.
FAU - Asano, Teizo
AU  - Asano T
AD  - Department of Antibody Drug Development, Tohoku University Graduate School of 
      Medicine, Sendai, Japan.
FAU - Kaneko, Mika K
AU  - Kaneko MK
AD  - Department of Antibody Drug Development, Tohoku University Graduate School of 
      Medicine, Sendai, Japan.
FAU - Kato, Yukinari
AU  - Kato Y
AUID- ORCID: 0000-0001-5385-8201
AD  - Department of Antibody Drug Development, Tohoku University Graduate School of 
      Medicine, Sendai, Japan.
AD  - Department of Molecular Pharmacology, Tohoku University Graduate School of 
      Medicine, Sendai, Japan.
LA  - eng
PT  - Journal Article
DEP - 20220802
PL  - United States
TA  - Monoclon Antib Immunodiagn Immunother
JT  - Monoclonal antibodies in immunodiagnosis and immunotherapy
JID - 101590955
RN  - 0 (Antibodies, Monoclonal)
RN  - 0 (Ccr2 protein, mouse)
RN  - 0 (Peptides)
RN  - 0 (Receptors, CCR2)
SB  - IM
MH  - Animals
MH  - *Antibodies, Monoclonal
MH  - Immunization
MH  - Mice
MH  - Peptides
MH  - *Receptors, CCR2
OTO - NOTNLM
OT  - CCR2
OT  - flow cytometry
OT  - monoclonal antibody
EDAT- 2022/08/03 06:00
MHDA- 2022/08/31 06:00
CRDT- 2022/08/02 17:13
PHST- 2022/08/03 06:00 [pubmed]
PHST- 2022/08/31 06:00 [medline]
PHST- 2022/08/02 17:13 [entrez]
AID - 10.1089/mab.2022.0001 [doi]
PST - ppublish
SO  - Monoclon Antib Immunodiagn Immunother. 2022 Aug;41(4):188-193. doi: 
      10.1089/mab.2022.0001. Epub 2022 Aug 2.